Quintet Private Bank Europe S.A. Acquires 151,636 Shares of Merck & Co., Inc. (NYSE:MRK)

Quintet Private Bank Europe S.A. lifted its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 216.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 221,657 shares of the company’s stock after buying an additional 151,636 shares during the period. Merck & Co., Inc. makes up about 1.5% of Quintet Private Bank Europe S.A.’s portfolio, making the stock its 21st largest position. Quintet Private Bank Europe S.A.’s holdings in Merck & Co., Inc. were worth $24,165,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRK. Norges Bank purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $3,108,366,000. Wellington Management Group LLP grew its position in Merck & Co., Inc. by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after purchasing an additional 5,196,914 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Merck & Co., Inc. by 14.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares during the last quarter. Bank of Nova Scotia grew its position in Merck & Co., Inc. by 352.2% during the 4th quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock worth $342,814,000 after purchasing an additional 2,449,211 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado grew its position in Merck & Co., Inc. by 29,914.1% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock worth $262,818,000 after purchasing an additional 2,402,700 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK traded up $0.11 during trading hours on Friday, hitting $129.48. The stock had a trading volume of 7,338,462 shares, compared to its average volume of 7,353,206. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The firm has a 50-day moving average price of $128.61 and a 200 day moving average price of $122.34. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The firm has a market capitalization of $327.95 billion, a price-to-earnings ratio of 143.87, a PEG ratio of 2.50 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same period in the previous year, the business posted $1.40 EPS. The business’s revenue was up 8.9% compared to the same quarter last year. As a group, research analysts anticipate that Merck & Co., Inc. will post 8.64 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is presently 342.22%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Argus raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Truist Financial boosted their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 4th. Finally, TheStreet cut shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Check Out Our Latest Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.